Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255


Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J.

Health Technol Assess. 2001;5(26):1-149. Review.


Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Prime D, de Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, Baines A, Moore A, Brealey N, Moynihan J.

J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):486-97. doi: 10.1089/jamp.2015.1224.


Novolizer: how does it fit into inhalation therapy?

Magnussen H.

Curr Med Res Opin. 2005;21 Suppl 4:S39-46; discussion S47.


Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD.

Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK.

Respir Med. 2008 Apr;102(4):593-604. Review.


Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.

Hantulik P, Wittig K, Henschel Y, Ochse J, Vahteristo M, Rytila P.

Pneumonol Alergol Pol. 2015;83(5):365-77. doi: 10.5603/PiAP.2015.0059.


The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.

Grant AC, Walker R, Hamilton M, Garrill K.

J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):474-85. doi: 10.1089/jamp.2015.1223. Erratum in: J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):218.


The clinical relevance of dry powder inhaler performance for drug delivery.

Demoly P, Hagedoorn P, de Boer AH, Frijlink HW.

Respir Med. 2014 Aug;108(8):1195-203. doi: 10.1016/j.rmed.2014.05.009.


Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD.

Schulte M, Osseiran K, Betz R, Wencker M, Brand P, Meyer T, Haidl P.

J Aerosol Med Pulm Drug Deliv. 2008 Dec;21(4):321-8. doi: 10.1089/jamp.2007.0634.


Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.

Svedsater H, Dale P, Garrill K, Walker R, Woepse MW.

BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72.


Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.

Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, Liu Z, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. Review.


Practical problems with aerosol therapy in COPD.

Rau JL.

Respir Care. 2006 Feb;51(2):158-72. Review.


Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.

Azouz W, Chetcuti P, Hosker H, Saralaya D, Chrystyn H.

BMC Pulm Med. 2015 May 1;15:47. doi: 10.1186/s12890-015-0043-x.


Importance of inhaler devices in the management of airway disease.

Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, Barnes PJ.

Respir Med. 2008 Jan;102(1):10-9. Review.


Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.

Molimard M, Till D, Stenglein S, Singh D, Krummen M.

Curr Med Res Opin. 2007 Oct;23(10):2405-13. doi: 10.1185/030079907X219698. Review.


Inhaled drug delivery in the hands of the patient.

Lavorini F.

J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):414-8. doi: 10.1089/jamp.2014.1132. Review.


[Easyhaler--ideal dry powder inhaler].

Andrzej E, Małgorzata BE.

Pol Merkur Lekarski. 2010 Apr;28(166):307-10. Review. Polish.


Dry powder inhalers in COPD, lung inflammation and pulmonary infections.

Muralidharan P, Hayes D Jr, Mansour HM.

Expert Opin Drug Deliv. 2015 Jun;12(6):947-62. doi: 10.1517/17425247.2015.977783. Review.


[Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].

Henriet AC, Marchand-Adam S, Mankikian J, Diot P.

Rev Mal Respir. 2010 Dec;27(10):1141-9. doi: 10.1016/j.rmr.2010.10.024. Review. French.

Items per page

Supplemental Content

Support Center